Statoil drops after 33% jump in profit falls short of Wall Street hopes
There’s no pleasing the market these days. Shares of Statoil (STO) fell 1.54% to $24.96 today after the company reported first quarter earnings of $4.4 billion, its highest quarterly profit in three years and 33% higher than in the first quarter of 2017. But the...
Monday buy of SolarEdge Technologies in my Jubak Picks portfolio
I’ve been looking for a way out of this investing puzzle for a while and I think I’ve finally found one. SolarEdge Technologies (SEDG). I’m adding these shares to my Jubak Picks Portfolio on Monday. And I’ll be buying call options on these...
New calculation: Current cash position in Jubak Picks Portfolio
A couple of readers have asked me So what’s the cash position in Jubak Picks now? Very good question to ask at a time when we’re all trying to manage risk in a volatile market. So from here on out I’m going to calculate an approximate cash position...
Selling copper pick Freeport McMoran on fears of U.S./China tariff war
Freeport McMoRan Copper and Gold (FCX) was the third and last copper stock I added to my portfolios back in January 12, 2018–after Southern Copper (SCCO) and First Quantum Minerals (FQMLF). I added so much copper since copper prices were soaring in 2017–up...
Turning around the Jubak Picks portfolio: It takes time (frustrating amounts of time) but by late 2016 the recovery was in place: 2017 total return 13.13% despite 27.2% cash
Turning around a portfolio can take a frustratingly long time. The Jubak’s Picks portfolio has had a performance problem since 2014. But I think I’ve finally put a recovery in place. The total return on the portfolio was 13.1% in 2017. That still badly...
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely...
Selling Acadia Pharmaceuticals out of my Jubak Picks portfolio
Today I’m selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...
Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate...
Diamondback Energy beats on earnings and starts dividend
After the close of New York trading today, Diamondback Energy (FANG) announced fourth quarter earnings of $1.56 a share (excluding one-time items). That beat the Wall Street consensus by 5 cents a share. Revenue climbed 116% year over year to $399 million, above...
China slides into correction too: Are Chinese stocks better buy on the dip candidates?
While our eyes have been glued to the volatility in U.S. markets, Chinese stocks have staged their own correction. The Shanghai Composite is down 12.1% from its high on January 24 to the low on Thursday, February 8. With the Lunar New Year and the week-long Spring...
Autoliv earnings beat and spinoff plans buck yesterday’s market plunge
While the Standard & Poor’s 500 stock index was falling 1.04% yesterday and the Dow Jones Industrial Average was giving up 362 point, auto safety supplier Autoliv (ALV) was busy climbing 8.07% on the day to close at $149.48. (The stock, a member of my Jubak...
Starbucks disappoints in quarter but recovery in 2018 is on track
Blame it on Christmas Tree Frappuccino. On Thursday, January 25, after the market close Starbucks (SBUX) reported December (fiscal 2018 first quarter) earnings of 58 cents a share (excluding one-time tax benefits.) The results were ugly on the revenue side where  the...
Caterpillar beats on earnings and guidance but stock falls 1.4% today
Investors and traders were determined to sell Caterpillar (CAT) shares after the stock gained 70% in 2017. That determination overshadowed yesterday’s good news on fourth quarter earnings and positive guidance for 2018. The shares, which I added to my Jubak...
Adding Boeing to Jubak Picks on weak dollar, strong global economy, tax cuts
Shares of Boeing (BA) have tumbled from $351.01 on January 17 to close at $334.69 today. I’m using the pull back to add shares to my Jubak Picks portfolio tomorrow, January 25. The Boeing story right now is one of multiple tailwinds pushing the stock higher. A...
Adding Caterpillar to my Jubak Picks and Volatility Portfolios ahead of earnings tomorrow
Caterpillar (CAT) looks to be a major beneficiary of the lower tax rates in the Tax Cuts & Jobs Act and for a lower U.S. dollar. (See today’s encouragement of a weaker dollar from Treasury Secretary Steve Mnuchin at Davos today.) Not that Caterpillar sales...
Turmoil isn’t done in lithium sector with volatility at SQM and ALB
The announcement of a deal between Sociedad QuÃmica y Minera de Chile (SQM) and Chile’s development agency CORFO that resolves a long-standing dispute on royalty rates and that would allow SQM to expand lithium production from the brines at government-owned...
Consumer Electronics Show caps great month for Synaptics
Shares of Synaptics (SYNA) closed up 13.35% today at $49.76 thanks to an upgrade to sector overweight from sector weight from KeyBanc Capital Markets and a very impressive showing for the company’s fingerprint technology for smartphones at the just concluded...
I’m adding copper exposure to my Jubak’s Picks Portfolio by moving Freeport McMoRan Copper & Gold from my 50 Stocks Portfolio
By this time I think you get the message: I like the trend in copper prices and copper stocks over the next five years. I’ve added copper producers South Copper (SCCO) to my long-term 50 Stocks Portfolio and First Quantum Minerals (FQVLF) to my volatility...
The challenges to rebalancing a portfolio in 2018–and some suggestions
2017 left investors with a huge challenge as we all move into 2018. After a 21.6% return on the Standard & Poor’s 500 stocks in 2017, do we let the money ride for 2018 or move it into other assets? Some stocks had almost unbelievable years in 2017. Amazon...
On the fourth day of Christmas my stock pick is Nvidia–and four colly birds
And what’s a colly bird and isn’t it “calling birds”? “Colly” derives from the Old English word for coal. So the song’s lyrics here call for four blackbirds. All the evidence I’ve seen argues that the use of “colly...
On the second day of Christmas my stock pick for 2018 is Nektar Therapeutics–and two-turtle doves
No point in hoping that Nektar Therapeutics (NKTR) will match this year’s gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid...
It’s beginning to look a lot like Christmas in Macao–and for MGM Resorts
The first ten days of December have been strong for gaming revenue in Macao. That has led investment company Sanford Bernstein to project that gaming revenue in Macao will climb 21% to 23% for the month. That would be stronger than expected–and bodes well for...
A reminder of why Jubak Pick Incyte has been so weak lately
On December 4 MacroGenics (MGNX) announced that it had closed on its previously announced (October 25) license agreement with Incyte (INCY). For an upfront payment of $150 million and up to $420 million in milestone payments Incyte gained the exclusive global rights...
Time to buy Incyte on the biotech dip
Maybe you didn’t even know there was a biotech dip. If all you’ve been following in the sector is a stock like Nektar Therapeutics (NKTR), a Jubak Picks member (and the call options are a holding in my Volatility Portfolio), you’re likely to respond...
Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say “Buy” in Jubak Picks even after this run
Nektar Therapeutics (NKTR) shares finished the day up 14.15% on fairly preliminary, but very important data from the trials of the company’s lead cancer drug. Those results go a long way to validating the company’s entire pipeline of drug candidates to...
Alibaba’s core business is going great; worries are at the investment margins
Yesterday before the market opened in New York China’s e-commerce giant Alibaba (BABA) reported September quarter earnings of $1.29 a share (excluding one-time items.) That was 26 cents a share better than Wall Street projections. Revenue climbed 61% to $8.63...
Autoliv soars on news that the company might split its auto businesses in two
Shares of Autoliv (ALV) soared today, closing up 12.26% to $127.14, on news that the company’s Board of Directors has authorized management to conduct a strategic review of splitting the current company into two new companies focused on passive auto safety and...
MGM shares climb on news stock is to join S&P 500
Effective July 26, MGM Resorts International (MGM) will join the Standard & Poor’s 500 stock index to replace Reynolds American (RAI), which is being acquired by British American Tobacco. (That means that all funds that track the S&P 500 index will...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!